ResMed, Inc.

Equities

RMD

US7611521078

Real-time Estimate Cboe BZX Other stock markets 11:18:18 20/09/2024 pm IST			5-day change	1st Jan Change
245.34 ^USD	+0.97%		-1.43%	+42.63%

18/09	Equity Markets Fall After 50-Basis-Point Fed Rate Cut	MT
18/09	Equity Markets Fall After 50-Basis-Point Fed Rate Cut	MT

Presentation Operator MessageOperator (Operator)Hello, and welcome to the Q4 Fiscal Year 2024 ...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about ResMed, Inc.

Equity Markets Fall After 50-Basis-Point Fed Rate Cut	19/09	MT
Equity Markets Fall After 50-Basis-Point Fed Rate Cut	19/09	MT
Sector Update: Health Care Stocks Fall	19/09	MT
US Equities Markets End Lower Wednesday After FOMC Cuts Rates	19/09	MT
Equity Markets Eke Out Gains Ahead of Fed Decision	18/09	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	18/09	MT
US Equity Indexes Rise in Choppy Trading Ahead of Fed's Policy Move, Guidance on Easing Path	18/09	MT
US Equity Indexes Decline as Investors Await Fed's Policy Move, Guidance on Easing Path	18/09	MT
Wolfe Research Downgrades ResMed to Underperform From Peer Perform, Price Target is $180	18/09	MT
Analyst recommendations: Blackstone, Resmed, Reddit, On Holding, Hiscox...	18/09
Resmed Insider Sold Shares Worth $1,262,800, According to a Recent SEC Filing	14/09	MT
ResMed Insider Sold Shares Worth $3,646,950, According to a Recent SEC Filing	11/09	MT
Resmed Insider Sold Shares Worth $479,800, According to a Recent SEC Filing	07/09	MT
ResMed Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:00 AM	04/09
Needham Downgrades ResMed to Hold From Buy	04/09	MT
ResMed Elects Christopher DelOrefice to the Board	16/08	CI
Resmed Insider Sold Shares Worth $2,166,000, According to a Recent SEC Filing	14/08	MT
Resmed Insider Sold Shares Worth $3,145,905, According to a Recent SEC Filing	09/08	MT
Resmed Insider Sold Shares Worth $10,419,552, According to a Recent SEC Filing	07/08	MT
UBS Adjusts Price Target on ResMed to $225 From $210, Maintains Neutral Rating	05/08	MT
Recession Fears Drag Australian Shares to More than Two-Month Low	05/08	MT
ResMed Shares Hit 52-Week High After Reporting Strong Results on Friday	05/08	MT
RBC Adjusts ResMed's Price Target to $206 From $204, Keeps Sector Perform Rating	02/08	MT
Mizuho Securities Adjusts ResMed Price Target to $230 From $220	02/08	MT
KeyBanc Adjusts Price Target on ResMed to $251 From $238	02/08	MT